Oseltamivir for infleunza

Drug and Therapeutics Bulletin

Volumn 40, Issue 12, 2002, Pages 89-91

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; METHOTREXATE; OSELTAMIVIR; PARACETAMOL; PLACEBO; SIALIDASE INHIBITOR; ZANAMIVIR; ACETAMIDE DERIVATIVE; ANTIVIRUS AGENT;

ARTICLE; BRONCHITIS; COST CONTROL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FLU LIKE SYNDROME; HEPATITIS; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; LICENSING; MORBIDITY; NAUSEA; OTITIS MEDIA; PNEUMONIA; UNITED KINGDOM; VOMITING; ADULT; ANTIBIOTIC RESISTANCE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACETAMIDES; ADULT; ANTIVIRAL AGENTS; CHILD; DRUG COSTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA, HUMAN; LICENSURE, PHARMACY; OSELTAMIVIR; RANDOMIZED CONTROLLED TRIALS;

EID: 0036985597     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2002.401289     Document Type: Article

References (18)

1. Tamiflu. Summary of product characteristics, UK/Ireland. Roche Ltd, June 2002.
2. Committee for Proprietary Medicinal Products (CPMP). European Public Assessment Report. Tamiflu. London: European Agency for the Evaluation of Medicinal Products. 2002.
3. Zanamivir for influenza. DTB 1999; 37: 81-4.
4. Why not zanamivir? DTB 2001; 39: 9-10.
5. Salisbury DM, Begg NT (Eds). Immunisation against infectious disease. London: HMSO, 1996.
6. Meier CP et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834-42.
7. Monto AS et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160: 3243-7.
8. Donaldson L et al. Influenza immunisation. Letter from the Chief Medical Officer, 1 August 2000. PL/CMO/2000/3. London: Department of Health, 2000.
9. Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343: 1778-87.
10. Gubareva LV et al. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-35.
11. Hayden FG et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336-43.
12. Welliver R et al. Effectiveness of oseltamivir in preventing influenza in household contacts. A randomised controlled trial. JAMA 2001; 285: 748-54.
13. Peters Jr PH et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025-31.
14. Ross AM et al. Presentation with influenza-like illness in general practice: implications for use of neuraminidase inhibitors. Commun Dis Public Health 2000; 3: 256-60.
15. Treanor JJ et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. A randomised controlled trial. JAMA 2000; 283: 1016-24.
16. Nicholson KG et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355: 1845-50.
17. Whitley RJ et al. Oral oseltamivir treatment of influenza in children. Paediatr Infect Dis J 2001; 20: 127-33.
18. Kaiser L et al. Oral oseltamivir reduces complications and hospitalizations resulting from influenza infection: a pooled analysis. 22nd International Congress of Chemotherapy, Amsterdam, June 30-July 3 2001 [abstract].